People · Operator
Named in public records as an officer, director or promoter · active 2018–2018 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Magenta Therapeutics, Inc. | — | Biotechnology | Series C | $116.0M | $2.1B | 2018 |
Zoran Zdraveski at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Zoran Zdraveski on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Bruce Booth | 1 | 12 |
| John Davis | 1 | 7 |
| Alexis Borisy | 1 | 6 |
| Blake Byers | 1 | 5 |
| JASON GARDNER | 1 | 5 |
| Thomas Daniel | 1 | 4 |
| Jeffrey Albers | 1 | 3 |
| Michael Bonney | 1 | 2 |
| David Scadden | 1 | 2 |
| Bastiano Sanna | 1 | 2 |
| Amy Ronneberg | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.